Moreover, all the 20 suspected cases were negative by the LFIA-IgM assay (Table?1). and specificity 2-Atractylenolide of LFIA-IgM/IgG and MCLIA-IgM/IgG assays for detecting SARS-CoV contamination were?>?90%, comparable with reverse transcription polymerase chain reaction detection. IgM antibody levels peaked on day 13 and began to fall on day 21, while IgG antibody levels peaked on day 17 and were maintained until tracking ended. Lymphocyte and subset enumeration suggested that lymphocytopenia occurred in patients with COVID-19. Conclusions LFIA-IgM/IgG and MCLIA-IgM/IgG assays can indicate SARS-CoV-2 contamination, which elicits an antibody response. Lymphocytopenia occurs in patients with COVID-19, which possibly weakens the T-cell response. Key Points Lateral flow immunochromatographic assay-IgM/IgG and magnetic chemiluminescence enzyme immunoassay-IgM/IgG assays can indicate SARS-CoV-2 contamination, which elicits an antibody response.Lymphocytopenia occurs in patients with COVID-19, which possibly weakens the T-cell response. Open in a separate windows Introduction According to the World Health Business report on 24 April, 2020, 2,591,015 coronavirus disease 2019 (COVID-19) cases were confirmed with 178,686 deaths globally. The novel severe acute respiratory coronavirus 2 (SARS-CoV-2) is the causative agent of the COVID-19 pandemic, and a lack of approved vaccines or specific treatments to SARS-CoV-2 leaves patients dependent on their own immune responses [1]. The SARS-CoV-2 single-stand RNA genome is usually?~?29.8?kb in length and encodes?~?28 proteins (four structural proteins, eight accessory proteins and 15 non-structural proteins) [1]. High infectivity, comparable syndromes and considerable mortality make laboratory diagnosis particularly important. Furthermore, laboratory diagnosis is critical to SARS-CoV-2 patient management, contact tracing and epidemiological studies. Timely diagnosis of suspected COVID-19 cases could reduce and 2-Atractylenolide interrupt the transmission of COVID-19 from person to person. Nucleic acid amplification assessments (NAT) and serological testing are two main laboratory testing methods [2C4]. IgM antibodies elicited immediately after coronavirus contamination indicate a current or new contamination, while IgG antibodies produced subsequently indicate recovery or a prior contamination [5, 6]. Therefore, antibody detection could indicate the occurrence of contamination and disease progress. Liu et al. [7] exhibited that an IgM/IgG assay for antibody detection was superior to real-time reverse transcription polymerase chain reaction (RT-PCR) for NAT, which is the gold standard for SARS-CoV-2 detection [8], and it also exhibited a lower false-negative rate [9, 10]. One of the main reasons for the high false-positive rate of RT-PCR assays is the difference between the main computer virus colonisation site (lower respiratory tract) and common sampling sites (upper respiratory tract) [9]. Unlike RT-PCR assays, antibody assays do not require sophisticated instruments, laboratory conditions or tedious experimental procedures. For example, the lateral flow immunochromatographic assay (LFIA) can be completed within 15 minutes without specialised gear or professionals. IgM and IgG antibodies appear earlier in severe patients than in non-severe patients, and their titres are significantly higher, indicating that a strong antibody response is usually associated with delayed viral clearance and disease severity [11]. The antibody level can be measured by a magnetic chemiluminescence enzyme immunoassay (MCLIA) to guide treatment during disease progression. The humoural immunity of patients can be evaluated by serological detection, as 2-Atractylenolide exemplified by quantitative detection of IgG and IgM [12], which provide essential complementary methods to NAT for pathogenic diagnosis. Cell-mediated immunity of patients can be evaluated by quantitative monitoring of lymphocytes and their subsets (e.g., T cells, CD4?+?T Nos3 cells and CD8?+?T cells), which are the primary effector cells [13]. Lymophocyte enumeration represents immune status on a daily clinical routine [14]. T cells coordinate multiple aspects of adaptive immunity to pathogens throughout life [15]. Naive T cells that play a central role in cell-mediated immunity fall into two 2-Atractylenolide large classes, including CD4?+?and CD8?+?T cells [16]. CD4?+?T cells differentiate into several subsets of effector T cells (T helper-1, T helper-2, T helper-17, regulatory T cells) that orchestrate different 2-Atractylenolide immune functions. CD8?+?T cells are critical for mediating clearance following many acute viral infections in the lung.